BAP Pharma Group Modern Slavery and Human Trafficking Statement

Introduction:

BAP Pharma Group are providing this statement outlining our ongoing commitment to acting ethically and with integrity in our business activities and throughout our supply chain. This statement also constitutes our systems that have been implemented and enforced to ensure slavery and human trafficking is not taking place anywhere across our business.

Due to the nature of our business, we fully understand that we have obligations to maintain a very high standard and conduct our business in a transparent and fair manner including compliance to all applicable laws and regulations.

In this context and in accordance with Section 54(1) of the Modern Slavery Act 2015, we (BAP Pharma Group) can provide assurance that our business model is free from slavery and human trafficking.

Business & Organisation Structure:

BAP Pharma Group constitutes three sites:

  • BAP Ltd which is the Company HQ in Slough, UK
  • BAP US Inc. with an office in New Jersey, USA
  • BAP GmBH with an office in Höchstädt an der donau, Germany

The company is fully privately owned by Dr Bashir Parkar and Mrs Nafisa Parkar with no outside investors.

BAP Pharma Group are global leaders in clinical trial supply, specialising in comparator sourcing and secondary packaging. We are driven to create exceptional value for our clients while offering unrivalled service. BAP Pharma Group are a truly global organisation with sites located in the UK, Germany and the USA. We are well-placed to understand clinical trial supply needs, and our long heritage means that we can truly deliver on our promise. BAP Pharma Group are fully licenced by the MHRA, New Jersey State Department of Health and Bavarian Health Authority (“Regierung von Oberbayern”).

BAP Pharma Group Supply Chain:

Our supply chain includes pharmaceutical companies and wholesalers. We procure pharmaceutical products directly from manufacturers and approved wholesalers and supply to other pharmaceutical companies for their clinical trials. Our supply chain is fully monitored covering audit programmes, supplier selection criteria, qualification and evaluation processes. This is in line with our internal procedures and Good Distribution Practice of Medicinal products for Human Use (2013/C 343/01).

BAP Pharma Group Policies, Ethics & Values:

BAP Pharma Group has a zero tolerance to slavery and human trafficking with a strong pledge towards an ethical trading policy. All employees are expected to understand and uphold our code of conduct and ethics including complying with all applicable laws, acting ethically and making business decisions that are consistent with our policies, ethics and values.

As a company committed to compliance, we are fully committed to ensuring that slavery and human trafficking are not taking place in any part of our business and supply chain.

Due Diligence for Anti-Slavery & Human Trafficking:

To ensure full compliance, we have suitable processes in place to:

  • Perform risk assessments to identify and evaluate risks within our supply chain
  • Continuously monitor risk areas within our supply chain and apply appropriate mitigative steps deemed necessary
  • Protect whistle blowers

BAP Pharma Group’s Continued Commitment:

As a company, we are in full recognition of the importance of complying with the relevant laws and regulations and to maintain a high standard capable of addressing any issues in relation to slavery and human trafficking within our supply chain.

We will undertake annual reviews and risk assessments of our strategy towards anti-slavery and human trafficking to ensure that our policies and processes driven by our management team is effectively embedded throughout our business model.

If we become aware that any part of our supply chain has failed to comply with our values relating to slavery and human trafficking, we shall take the appropriate steps to address the issue and maintain compliance at all times.

Signed and Approved on behalf of BAP Pharma Group.

Dr Bashir Parkar
Managing Director